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Abstract
Background: We have shown that insertion of the three vaccinia virus (VACV) promoter-driven foreign gene
expression cassettes encoding Renilla luciferase-Aequorea GFP fusion protein, b-galactosidase, and b-glucuronidase
into the F14.5L, J2R, and A56R loci of the VACV LIVP genome, respectively, results in a highly attenuated mutant
strain GLV-1h68. This strain shows tumor-specific replication and is capable of eradicating tumors with little or no
virulence in mice. This study aimed to distinguish the contribution of added VACV promoter-driven transcriptional
units as inserts from the effects of insertional inactivation of three viral genes, and to determine the correlation
between replication efficiency of oncolytic vaccinia virus in cell cultures and the virulence and antitumor efficacy in
mice
Methods: A series of recombinant VACV strains was generated by replacing one, two, or all three of the expression
cassettes in GLV-1h68 with short non-coding DNA sequences. The replication efficiency and tumor cell killing
capacity of these newly generated VACV strains were compared with those of the parent virus GLV-1h68 in cell
cultures. The virus replication efficiency in tumors and antitumor efficacy as well as the virulence were evaluated in
nu/nu (nude) mice bearing human breast tumor xenografts.
Results: we found that virus replication efficiency increased with removal of each of the expression cassettes. The
increase in virus replication efficiency was proportionate to the strength of removed VACV promoters linked to
foreign genes. The replication efficiency of the new VACV strains paralleled their cytotoxicity in cell cultures. The
increased replication efficiency in tumor xenografts resulted in enhanced antitumor efficacy in nude mice. Similarly,
the enhanced virus replication efficiency was indicative of increased virulence in nude mice.
Conclusions: These data demonstrated that insertion of VACV promoter-driven transcriptional units into the viral
genome for the purpose of insertional mutagenesis did modulate the efficiency of virus replication together with
antitumor efficacy as well as virulence. Replication efficiency of oncolytic VACV in cell cultures can predict the
virulence and therapeutic efficacy in nude mice. These findings may be essential for rational design of safe and
potent VACV strains for vaccination and virotherapy of cancer in humans and animals.
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Background
At least 7 million people die from cancer worldwide
every year, with an estimated 12 million deaths in 2030
[1]. In the Unites States, one in two men and one in
three women will be diagnosed with cancer, and one in
four Americans will die from this disease [2]. Currently,
the principal cancer treatment methods are surgery,
radiotherapy, and chemotherapy. Although a great deal
of efforts have been made to improve these conventional
therapies, they are generally ineffective in treating
patients with advance cancer. Thus, new treatments are
urgently needed.
In the last two decades, considerable progress has
been achieved in the field of oncolytic virotherapy.
Oncolytic viruses have emerged as promising cancer
* Correspondence: aaszalay@genelux.com
1Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA
Full list of author information is available at the end of the article
Chen et al. Journal of Translational Medicine 2011, 9:164
http://www.translational-medicine.com/content/9/1/164
© 2011 Chen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.therapeutic agents. Since the first genetically engineered
oncolytic virus (oncolytic adenovirus ONYX-015)
entered clinical trials in 1996, many oncolytic virus con-
structs from at least seven different species have been
tested in a variety of clinical trials. Clinical data indi-
cates that oncolytic viruses are generally safe in cancer
patients. Furthermore, virus replication within tumors
and a certain degree of therapeutic efficacy have also
been reported in clinical trials [3]. Oncolytic viruses
destroy tumors by several mechanisms [3], including
intrinsic antitumor activity, induction of host antitumor
immune responses, destruction of the tumor vasculature
[4], and expression of therapeutic genes. The impor-
tance of each mechanism has yet to be determined.
Oncolytic virotherapy can also effectively complement
conventional cancer therapies, such as chemo- and
radiotherapy.
Vaccinia virus (VACV) was used as a vaccine to eradi-
cate smallpox that is estimated to have killed 500 million
people in the 19
th and 20
th Centuries [5]. Thus, it is argu-
ably the most successful live biotherapeutic agent. VACV
is also the first oncolytic virus demonstrating viral oncoly-
sis in the laboratory [6,7]. Many oncolytic VACVs have
been tested in preclinical and clinical studies [8]. Owing to
safety concerns, most of the oncolytic VACVs developed
in recent years have been attenuated, mainly through viral
gene inactivation. The following genes have been inacti-
vated, either singly or in combination [8]: F14.5L, hemag-
glutinin (HA), serine protease inhibitor-1 (SPI-1), soluble
type I interferon (IFN) receptor, SPI-2, thymidine kinase
(TK), and vaccinia growth factor (VGF). It is noted that
over-attenuation may affect antitumor efficacy. For exam-
ple, a VACV triple mutant lacking SPI-1, SPI-2, and TK
was reported to be greatly attenuated in mice. However, it
also replicated in general less efficiently in tumor cells in
culture, and its overall antitumor efficacy was lower than
the parental viruses [9]. So far, the correlation between
viral replication efficiency in tumor cells in culture and
antitumor efficacy has not been established.
We have previously reported a light-emitting oncolytic
VACV, GLV-1h68, which was constructed by inserting
three foreign gene expression cassettes encoding Renilla
luciferase-Aequorea green fluorescent protein fusion pro-
tein (RUC-GFP), b-galactosidase, and b-glucuronidase
into the F14.5L, J2R, and A56R loci within the genome of
VACV LIVP, respectively [10]. GLV-1h68 was greatly
attenuated compared with its parent viruses [10,11].
Here, we report on the construction of a series of recom-
binant VACVs with fine-tuned replication efficiency by
r e p l a c i n go n e ,t w o ,o ra l lt h ree of these expression cas-
settes with short non-coding DNA sequences. We found
that virus replication efficiency increased with removal of
each of the expression cassettes. The increase in virus
replication efficiency was proportionate to the strength of
removed VACV promoters linked to foreign genes. Using
this series of recombinant VACVs, we demonstrated that
increased viral replication efficiency in cell cultures cor-
related with enhanced therapeutic efficacy, but also with
increased virulence in nude mice with solid human
tumor xenografts.
Materials and methods
Virus and cell culture
The human breast ductal adenocarcinoma cell line
GI-101A [12] was kindly provided by Dr. A. Aller (Rum-
baugh-Goodwin Institute for Cancer Research, Inc.) and
was cultured in RPMI 1640 supplemented with 5 ng/mL
of b-estradiol and progesterone (Sigma, St. Louis, CA),
10 mmol/L HEPES, 1 mmol/L sodium pyruvate, 20% fetal
bovine serum (FBS; Mediatech, Inc., Manassas, VA), and
1% antibiotic-antimycotic solution (Mediatech, Inc., Man-
assas, VA). African green monkey kidney fibroblast CV-1
cells were purchased from American Type Culture Collec-
tion (Manassas, VA, USA) and were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% FBS at
37°C under 5% CO2. GLV-1h68 was derived from VACV
LIVP (Lister strain from the Institute of Viral Preparations,
Moscow, Russia), as described previously [10].
Construction of VACV shuttle vectors and generation of
recombinant VACVs
The VACV J2R (TK) shuttle vector pCR-TKLR-gpt2 con-
tains the left and right flanking sequences of VACV J2R
separated by Kpn I, Sac I, and BamH I, and Escherichia
coli guanine phosphoribosyltransferase (gpt)g e n ed r i v e n
by the VACV early promoter p7.5 as a transient dominant
selectable marker. The left flank of the TK locus in the
LIVP genome was PCR amplified with the primers TKL-5
(5’-ATAAGCTTTGTTACAGATGGAAGGGTCAAA-3’)
and TKL-3 (5’-AGGTACCGTTTGCCATACGCTCA-
CAGA-3’) using Invitrogen High Fidelity PCR mix (Invi-
trogen, Carlsbad, CA). The right flanking region of the TK
locus in the LIVP was PCR amplified with the primers
TKR-5 (5’-TGAGCTCGGATCCTTCTGTGAGCGTA
TGGCAAA-3’)a n dT K R - 3( 5 ’-TTACTAGTACAC-
TACGGTGGCACCATCT-3’). To construct VACV A56R
(HA) shuttle vector, the left and right flanking sequences
of VACV A56R were PCR-amplified from VACV LIVP
using Platinum PCR SuperMix High Fidelity (Invitrogen,
Carlsbad, CA) and the primers: 5’-GCGCATATGACAC-
GATTACCAATACTTTTG-3’ and 5’-GTCGGGATCCT
GCGAAGCTTAGATTTCGAATACCGACGAGC-3’ (left
flank), 5’-GAAATCTAAGCTTCGCAGGATCCCGAC
TCCGGAACCAATTACTG-3’ and 5’-GCGGAATTCT-
GATAGATTTTACTATCCCAG-3’ (right flank). The two
fragments were joined together using the method of gene-
splicing by overlapping extension [13]. The resulting frag-
ment was digested with Nde I and EcoR I and cloned into
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flanking sequences of A56R in the target vector were con-
firmed by sequencing. The VACV F14.5L shuttle vector
pNCVVf14.5lT was constructed as described previously
[11].
The recombinant viruses GLV-1h70, GLV-1h71, and
GLV-1h72 were generated from the parental virus GLV-
1h68 using pNCVVhaT, pNCVVf14.5lT, and pCR-
TKLR-gpt2, respectively. GLV-1h73 was generated from
GLV-1h70 using pNCVVf14.5lT, and GLV-1h74 from
GLV-1h73 using pCR-TKLR-gpt2. All recombinant
viruses were constructed using the method described
previously [14].
Viral growth curves
GI-101A cells grown in 6-well plates were infected with
individual virus strains at a multiplicity of infection (MOI)
of 0.01 or 10. Three wells of GI-101A cells infected indivi-
dually with each virus strain were harvested at 24, 48, and
72 h post-infection (hpi). Viral particles from the infected
cells were released by three cycles of freeze-thaw, followed
by sonicating three times for 1 min at full power using the
Branson sonifier 450 before titration. Virus strains were
titrated in CV-1 cells in duplicates.
Cytotoxicity assays in cell culture
Cytotoxcity was performed as described previously [14].
Briefly, GI-101A cells were plated at 2 × 10
4 cells per well
in 96-well plates and incubated at 37°C in a CO2 incubator
overnight. Cells were either mock-infected or infected with
each virus strain at an MOI of 0.01. Viral cytotoxity was
assayed daily for 5 d. Lactate dehydrogenase (LDH) activ-
ity was quantified using a CytoTox 96 Non-Radioactive
Cytotoxicity Assay kit (Promega, Madison, WI). Results
are expressed as the percentage of surviving cells. This
percentage was determined using the formula: (cell lysate-
supernatant)tx/(cell lysate-supernatant)t0 × 100. In the
formula, (cell lysate-supernatant)tx and (cell lysate-super-
natant)t0 represent LDH activity in the cells after and
before infection, respectively.
Virus virulence and tumor therapy in mice
All mice were cared for and maintained in accordance
with animal welfare regulations under an approved proto-
col by the Institutional Animal Care and Use Committee
of Explora Biolabs (San Diego Science Center, San Diego,
CA). GI-101A xenograft tumors were developed in 6- to
8-week-old male nude mice (NCI:Hsd:Athymic Nude-
Foxn1
nu, Harlan) by implanting 5 × 10
6 GI-101A cells sub-
cutaneously on the right hind leg. Tumor growth was
recorded once a week in three dimensions using a digital
caliper. Tumor volume was calculated as ([length × width
× height]/2) and reported in mm
3. Thirty-three days after
tumor cell implantation, mice were injected with a single
intravenous dose of 5 × 10
6 plaque forming units (pfu) of
individual virus strains in 100 μLo fP B S .A n i m a l sw e r e
observed daily for any sign of virulence. Fourteen days
post virus injection, four animals from each group were
sacrificed for analysis of virus titers in tumors as described
previously [10].
Statistical analysis
Statistical analyses were performed with GraphPad
Prism, version 5.03 (GraphPad Software Inc., San Diego,
CA). Comparisons of treatment groups were made by
either unpaired t test or two-way analysis of variance
(ANOVA) with Bonferroni comparison post-tests as
indicated in the figure legends. The post-test was only
performed when ANOVA revealed significance. Statisti-
cal analysis of survival was assessed using the log-rank
test. Values of P less than 0.05 were considered
significant.
Results
Generation of the derivatives of GLV-1h68 by replacing
the foreign gene expression cassettes with short non-
coding DNA sequences
Previously, we have shown that insertion of the foreign
marker gene expression cassettes into the F14.5L, J2R
(encoding thymidine kinase, TK), and A56R (encoding
hemagglutinin, HA) loci of the VACV LIVP genome dis-
rupted the open-reading frames (ORFs) F14.5L, J2R,a n d
A56R, resulting in the recombinant VACV GLV-1h68
with enhanced tumor colonization specificity as well as
reduced virulence in mice [10,11]. To determine the con-
tributions of individual foreign gene expression to virus
attenuation, in addition to viral gene inactivation, we con-
structed a series of the derivatives of GLV-1h68 by repla-
cing one, two, or all three of these expression cassettes in
t h eg e n o m eo fG L V - 1 h 6 8w i t hs h o r tn o n - c o d i n gD N A
sequences while the original ORFs F145L, J2R,a n dA56R
remain disrupted in all the derivatives. The RUC-GFP
expression cassette at the F14.5L locus was replaced with
the short DNA sequence “GGATCCTGCGAAGCTT“
comprising BamH Ia n dHind III sites (underlined). The
foreign inserts (human transferin receptor and lacZ) at the
J2R locus were replaced with the non-coding DNA
sequence “CTGTGAGCGTATGGCAAACGGTACC-
GAGCTCGGATCC” consisting of Kpn I, Sac I, and
BamH I sites. The b-glucuronidase expression cassette at
the A56R locus was replaced with the short DNA
sequence “TAAGCTTCGCAGGATCCC” comprising
Hind III and BamH I sites. The genotype of each deriva-
tive shown in Figure 1A was verified by PCR, followed by
DNA sequencing. The statuso fe x p r e s s i o no fG F P ,b-
galactosidase, and b-glucuronidase by each derivative was
confirmed by fluorescence microscopy, 5-bromo-4-chloro-
3-indolyl-b-D-galactopyranoside (X-gal), or 5-bromo-4-
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Page 3 of 11Figure 1 GLV-1h68 and its derivatives. (A) Schematic representation of the genomic structures of the recombinant vaccinia virus GLV-1h68
and its marker gene expression cassette removal derivatives. PE/L, P11, and P7.5 are VACV synthetic early/late, 11K, and 7.5K promoters,
respectively. TfR is human transferin receptor inserted in the reverse orientation with respect to the promoter PE/L. (B) Marker gene expression
and genotype verification. CV-1 cells were infected with each individual virus strain. Two days post-infection, the GFP expression was visualized
by fluorescence microscopy and expression of b-galactosidase and b-glucuronidase was detected by X-gal and X-GLcA staining, respectively.
Chen et al. Journal of Translational Medicine 2011, 9:164
http://www.translational-medicine.com/content/9/1/164
Page 4 of 11chloro-3-indolyl-b-D-glucuronic acid (X-GlcA) staining,
respectively (Figure 1B).
Excision of the foreign expression cassettes from GLV-
1h68 enhances virus replication efficiency in cell cultures
To examine whether removal of any of the originally
introduced foreign gene expression cassettes from GLV-
1h68 would affect virus replication, human breast tumor
GI-101A cells in culture were infected with the parental
virus GLV-1h68 and its derivatives at an MOI of 0.01 or
10. The infected cells were harvested at 24, 48, and
72 hpi and the viral titers at each time point determined
in CV-1 cells using standard plaque assays. At the MOI
of 0.01, GLV-1h71 (RUC-GFP
-), GLV-1h73 (RUC-GFP
-/
gusA
-), and GLV-1h74 (RUC-GFP
-/lacZ
-/gusA
-)s h o w e d
significantly enhanced virus replication at all time points
examined, whereas GLV-1h70 (gusA
-) and GLV-1h72
(lacZ
-) demonstrated significantly better virus replication
a t4 8a n d7 2h p i ,b u tn o ta t2 4h p i ,c o m p a r e dw i t ht h e
parent virus GLV-1h68 (Figure 2A). At the MOI of 10,
GLV-1h71 (RUC-GFP
-), GLV-1h73 (RUC-GFP
-/gusA
-),
and GLV-1h74 (RUC-GFP
-/lacZ
-/gusA
-)s h o w e ds i g n i f i -
cantly higher replication efficiency at 48h, 72h, and all
time points, respectively, than GLV-1h68 (Figure 2A).
The difference in virus replication among all the viruses
was more prominent at the low MOI (0.01) than that at
the high MOI (10). Furthermore, GLV-1h71 (RUC-GFP
-
), GLV-1h73 (RUC-GFP
-/gusA
-), and GLV-1h74 (RUC-
GFP
-/lacZ
-/gusA
-) formed significantly larger plaques
than GLV-1h68 in GI-101A cells (Figure 2B). The pla-
ques formed by GLV-1h70 (gusA
-) and GLV-1h72 (lacZ
-
)w e r ec o n s i s t e n t l ys l i g h t l yl a r g e rt h a nt h a tf o r m e db y
GLV-1h68. However, the differences in plaque size
among GLV-1h68, GLV-1h70 (gusA
-), and GLV-1h72
(lacZ
-) were not statistically significant. Taken together,
removal of any of the foreign expression cassettes or in
combination, enhanced virus replication in each cell
lines, irrespective of which foreign gene was removed.
Among three foreign expression cassettes within the
genome of GLV-1h68, removal of the RUC-GFP expres-
sion cassette had the greatest enhanced effect on virus
replication. GLV-1h73 (RUC-GFP
-/gusA
-)w i t ht w oo f
the foreign gene expression cassettes removed, repli-
cated more rapidly than any of the single foreign gene
expression cassette removal viruses, whereas GLV-1h74
(RUC-GFP
-/lacZ
-/gusA
-) in which all three foreign
expression cassettes were replaced, demonstrated the
highest replication efficiency among all the virus strains
tested. Thus, a series of recombinant VACV strains with
fine-tuned replication efficiency were generated by
replacing one, two, or three expression cassettes in the
genome of GLV-1h68 with short non-coding DNA
sequences.
Replication efficiency of GLV-1h68 and its derivatives in
cell cultures inversely correlates with added strength of
the inserted promoters remaining in each viral genome
As demonstrated above, replication efficiency of GLV-
1h68 and its derivatives in cell cultures was inversely pro-
portionate with the number of foreign gene expression
cassettes present in the viral genome. Among the single
foreign gene expression cassette removal derivatives,
GLV-1h71 (RUC-GFP
-) showed the highest replication
efficiency. It is interesting to note that the RUC-GFP
expression cassette that was replaced in GLV-1h71 con-
tains a synthetic early/late promoter (PE/L), the strongest
promoter among the promoters introduced into the
genome of GLV-1h68 [15]. It is likely that the extra tran-
scriptional and translational burden imposed by over-
expression of the foreign gene expression cassettes might
slow down virus replication. Since an extra transcrip-
tional and translational burden is directly related to the
strength of a promoter, we sought to analyze the relation-
ship between the replication efficiency of the GLV-1h68
derivatives and the strength of the inserted promoters
remaining in each viral genome. Firstly, we assigned an
index to each promoter according to their strength as
reported before [15]. The index of the VACV P7.5 K pro-
moter (P7.5) was set to 1, and the indices of the VACV
P11K promoter (P11) and PE/L were 24.5 and 49.2,
respectively, since P11 and PE/L were reported to be 24.5
and 49.2 times stronger than P7.5, respectively [15]. The
index of PE/L at the J2R locus was half of the index of
the PE/L at the F14.5L locus (24.6) since the gene encod-
ing human transferring receptor was inserted in the
reverse orientation with respect to the promoter. Sec-
ondly, the promoter scores for GLV-1h68 and its deriva-
tives were calculated by adding together the index of
each inserted promoter remaining in each virus strain.
The resulting promoter scores for GLV-1h68, GLV-1h70
(gusA
-), GLV-1h71 (RUC-GFP
-), GLV-1h72 (lacZ
-),
GLV-1h73 (RUC-GFP
-/gusA
-), and GLV-1h74 (RUC-
GFP
-/lacZ
-/gusA
-) were 99.3, 74.8, 50.1, 73.7, 25.6, and 0,
respectively. Regression analysis indicated that there was
an inverse correlation between the promoter scores and
the virus replication efficiency in the GI-101A cell culture
with a value of R
2 being 0.9968 (Figure 2C). Thus, repli-
cation efficiency of GLV-1h68 and its derivatives in the
cell culture inversely correlated with added strength of
the inserted promoters remaining in each viral genome.
Foreign gene expression cassette removal derivatives kill
tumor cells in culture more efficiently than their parental
virus GLV-1h68
After demonstrating that vaccinia virus replication effi-
ciency in cell cultures was inversely proportionate to the
number of foreign gene expression cassettes present
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the strength of promoters inserted into each viral gen-
ome, we compared the tumor cell-killing potential of
each virus strain. Human breast tumor GI-101A cells
were infected with each virus strain at an MOI of 0.01,
and cell viability was measured daily for 5 d after infec-
tion. In general, the number of viable cells continued to
increase until 2d after infection owing to the fact that
only a small portion of cells was initially infected at the
low MOI. Compared with mock infection, GLV-1h68
infection resulted in a significant decrease in the num-
ber of viable cells at 96 and 120 hpi (P < 0.01, 0.001,
respectively). All foreign gene expression cassette
removal derivatives showed significantly more efficient
tumor cell killing than their parent virus GLV-1h68 at
certain time points after infection (Figure 3). There was
a general trend that virus strains with higher replication
efficiency also killed cancer cells more efficiently. Thus,
virus replication efficiency was in accord with its tumor
cell-killing capacity.
Replication efficiency of GLV-1h68 and its derivatives in
tumor xenografts positively correlates with their
replication efficiency in cell cultures
To compare replication efficiency of GLV-1h68 and each
of its derivatives in tumor xenografts, nude mice bearing
Figure 2 Excision of the foreign expression cassettes from GLV-1h68 enhances virus replication efficiency. (A) Viral growth curves. GI-
101A cells were infected with GLV-1h68 or its derivatives at an MOI of 0.01 or 10, and harvested at 24, 48, and 72 hpi. Viral titers were
determined in CV-1 cells. The values are the mean of triplicate samples, and the bars indicate SD. The data represents two independent
experiments. Statistical analysis was performed using two-way ANOVA. *, **, and *** indicate P < 0.05, 0.01, and 0.001, respectively, when
compared with the GLV-1h68 group. (B) Plaque size comparison. Human breast tumor GI-101A cells were infected with 200 pfu of each virus
strain for three days, and stained with crystal violet. The values are the mean of more than 58 plaques, and the bars indicate SD. Representative
of two independent experiments. Statistical analysis was performed using unpaired t-test. GLV-1h71, GLV-1h73, and GLV-1h74 formed
significantly larger plaques then did GLV-1h68. *** indicates P < 0.001 when compared to GLV-1h68. (C) Correlation between the promoter
scores of GLV-1h68 and its derivative with their virus yields in the GI-101A cell culture (48 hpi, MOI 0.01).
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with each virus strain at 5 × 10
6 pfu per mouse. Tumors
were harvested at 14 days post virus administration. Viral
titers in tumors were determined in CV-1 cells using
standard plaque assays. As shown in Figure 4A, GLV-
1h73 (RUC-GFP
-/gusA
-) and GLV-1h74 (RUC-GFP
-/
lacZ
-/gusA
-) with two and three of the foreign expression
cassettes removed, respectively, gave significantly higher
virus yields than their parental virus GLV-1h68. Although
there was no statistically significant difference in virus
yield between GLV-1h68 and single cassette-replaced
virus strains, these virus strains consistently gave higher
virus yields than GLV-1h68 in the GI-101A and other dif-
ferent tumor models tested (Figure 4A). Regression analy-
sis indicated that there was a linear correlation between
virus yields in the GI-101A tumors and that in the
GI-101A cell culture (Figure 4B).
Enhanced virus replication efficiency predicts enhanced
antitumor efficacy
After demonstrating that removal of the marker gene
expression cassettes enhanced virus replication and
tumor cell killing in cell cultures as well as virus replica-
tion in tumors, we sought to determine if enhanced virus
replication could be translated into improved therapeutic
efficacy. Nude mice bearing the GI-101A tumors of 200-
300 mm
3 were injected i.v. with each virus strain at a
single dose of 5 × 10
6 pfu/mouse. Tumor volume was
monitored weekly for 84 days. As depicted in Figure 5A,
not surprisingly, GLV-1h68 efficiently shrank the
GI-101A tumors as demonstrated before [10]. All the
derivatives showed enhanced tumor-shrinking capability
compared with the parental virus GLV-1h68. Strikingly,
tumors treated with GLV-1h74 (RUC-GFP
-/lacZ
-/gusA
-)
with all of the foreign expression cassettes excised,
stopped growing three weeks after virus administration,
which was two weeks earlier than the date when GLV-
1h68-treated tumors ceased to grow. Overall, virus
strains that replicated more efficiently in the GI-101A
cell culture, also shank the GI-101A tumors faster.
Enhanced virus replication efficiency predicts increased
virulence in nude mice
To evaluate if removal of the foreign gene expression cas-
settes from GLV-1h68 would affect virus virulence in
mice, groups of 6 nude mice bearing the GI-101A tumors
were treated with each virus strain individually as
described above for the efficacy study (untreated group
had 4 mice). Mouse survival was monitored daily. Due to
excessive tumor burden, all untreated mice were sacri-
ficed 102 days after tumor cell implantation (equivalent
to 68 days post treatment for the treated groups). All
treated groups were observed for 84 days after virus
treatment. During this period, all mice treated with GLV-
1h71 (RUC-GFP
-) survived and looked healthy. Two
mice each treated with GLV-1h68 or GLV-1h72 (lacZ
-)
died. Three, 5, and all 6 mice treated with GLV-1h70
(gusA
-), GLV-1h73 (RUC-GFP
-/gusA
-), and GLV-1h74
Figure 3 Foreign gene expression cassette removal derivatives kill tumor cells in culture more efficiently than their parental virus
GLV-1h68. GI-101A cells were infected with each virus strain at an MOI of 0.01. Cell viability was determined using CytoTox 96 Non-Radioactive
Cytotoxicity Assay kit (Promega, Madison, WI, USA). Cell survival before infection was set at 100%. The values are the mean of quadruplicate
samples, and the bars indicate SD. The data represents two independent experiments. Statistical analysis was performed using two-way ANOVA.
*, **, and *** indicate P < 0.05, 0.01, and 0.001, respectively, when compared with the GLV-1h68 group.
Chen et al. Journal of Translational Medicine 2011, 9:164
http://www.translational-medicine.com/content/9/1/164
Page 7 of 11(RUC-GFP
-/lacZ
-/gusA
-) died, respectively. Statistically,
there was a significant difference in survival between the
GLV-1h68 treated group and the GLV-1h74-treated
group, but no significant difference between GLV-1h68
treated group and any other virus-treated groups (Figure
5B). Thus, excision of one of the foreign expression cas-
settes from GLV-1h68 seemed not to significantly affect
virus virulence, whereas removal of all of three foreign
expression cassettes significantly enhanced virus viru-
lence. Although there was no significant difference in
survival between GLV-1h68 treated group and GLV-
1h73 (RUC-GFP
-/gusA
-) treated group, we consistently
observed higher virulence associated with GLV-1h73
(RUC-GFP
-/gusA
-) than GLV-1h68 in additional tumor
Figure 4 Virus growth in GI-101A tumor xenografts positively correlates with virus yields in cell cultures. (A) Viral titers in the GI-101A
tumors. Nude mice bearing the GI-101A tumors were injected i.v. with each virus strain at 5 × 10
6 pfu/mouse. Tumors were harvested at 14
days post virus administration. The values are the mean of quadruplicate samples, and the bars indicate SD. Statistical analysis was performed
using unpaired t test with Welch’s correction. * indicates P < 0.05, when compared with the GLV-1h68 group. (B) Correlation between virus
yields in the GI-101A cell culture (48 hpi, MOI 0.01) and virus growth in the GI-101A tumors.
Figure 5 Virus replication efficiency in cell cultures predicts antitumor efficacy and virulence in nude mice with tumor xenografts.
Tumor-bearing mice (n = 6) were injected i.v. with each virus strain at a single dose of 5 × 10
6 pfu/mouse at 34 days after tumor cell
implantation. Tumor volume (A) and mouse survival (B) were monitored for 84 days after virus administration. Statistical analysis of the survival
data was performed using the log-rank test. * indicates P < 0.05, when compared with the GLV-1h68 group. All untreated mice were sacrificed
102 days after tumor cell implantation (equivalent to 68 days post treatment for the treated groups).
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directly reflected the replication efficiency of these virus
strains in cell cultures.
Discussion
GLV-1h68, one of the most widely studied oncolytic
VACVs, has been shown to be effective in treating large
numbers of human and canine cancers in preclinical stu-
dies [10,16-24]. It is currently being evaluated in phase
I/II clinical trials http://www.clinicaltrials.gov. GLV-1h68
was derived from the wild-type VACV LIVP by inser-
tional inactivation of the ORFs F14.5L, J2R,a n dA56R
[10]. Our previous studies demonstrated that GLV-1h68
was much attenuated in nude mice compared with its
parental virus strains [10,11]. Inactivation of F14.5L, J2R,
and A56R was previously shown to reduce VACV viru-
lence in mice [11,25-27]. In this study, we decided to
determine how much the expression of foreign marker
genes, in addition to viral gene interruption, contributed
to the level of attenuation of GLV-1h68. When an indivi-
dual foreign gene expression cassette was replaced with a
short non-coding DNA sequence, replacement of any
single expression cassettes resulted in elevated replication
in cell cultures compared to their parent virus GLV-1h68.
Replacement of the RUC-GFP expression cassette
resulted in the most enhanced virus replication, probably
owing to the fact that the synthetic early/late promoter
that drives RUC-GFP expression is the strongest in com-
parison with the other promoters [15]. GLV-1h73 (RUC-
GFP
-/gusA
-) with two of the foreign gene expression cas-
settes removed replicated more efficiently than any of the
virus strains with single foreign gene expression cassette
removed. GLV-1h74 (RUC-GFP
-/lacZ
-/gusA
-)i nw h i c h
all three foreign expression cassettes were replaced,
demonstrated the highest replication efficiency among all
the virus strains tested. Interestingly, we have noticed
that replication efficiency of GLV-1h68 and its foreign
gene removal derivatives was inversely proportionate to
the added strength of the promoters present at the loci of
F14.5L, J2R,a n dA56R in each virus strain. Thus, the
expression of the foreign genes driven by the VACV pro-
moters that adds an extra transcriptional and transla-
tional burden onto the virus and infected cells
contributed to the attenuation of GLV-1h68 replication.
Since the degree of attenuation of VACV strains is pro-
portionate to the strength of promoters that drive foreign
gene expression, therefore, it may be possible to fine tune
VACV replication efficiency by choosing VACV promo-
ters of appropriate strength to facilitate foreign gene
expression in VACV as was demonstrated for the first
time in this study.
The mechanisms by which oncolytic viruses destroy
tumors are currently under intense investigation. It is
believed that an unarmed oncolytic virus destroys tumors
through one, or most likely, a combination of the follow-
ing mechanisms: 1) by direct viral oncolysis of tumor
cells; 2) by destruction of the tumor vasculature [4,28];
and 3) by induction of host antitumoral immune
responses [29,30]. However, importance of each mechan-
ism is still a matter of controversy, and might be depen-
dent on types of tumors, viruses, and hosts studied. Kirn
et al. reported that a VACV WR-derived oncolytic virus
infected tumor-associated vascular endothelial cells,
resulting in vascular collapse in infected tumors [31]. In
c o n t r a s t ,w er e c e n t l ys h o w e dt h a tt h eo n c o l y t i cV A C V
GLV-1h68 did not destroy endothelial cells in tumors.
The tumor vasculature in infected tumors was still func-
tional [32]. These differences in the results might reflect
differences in the cell tropisms of VACV WR and LIVP
derived virus strains, and/or might be tumor type depen-
dent. In a study investigating the role of antitumor
immunity in comparison to the role of direct oncolysis in
reovirus-mediated virotherapy, Prestwich et al. found
that the immune response, but not direct viral oncolysis
or replication, was a critical factor for reovirus-mediated
tumor rejection or therapy [33]. Previously, we reported
massive VACV-mediated intratumoral inflammations in
GLV-1h68-infected tumors [10]. However, following stu-
dies indicated that VACV-mediated immune responses
were not essential for tumor elimination [32]. Instead,
viral-mediated direct tumor cell killing seems to be a key
factor for GLV-1h68-mediated oncolytic virotherapy,
suggesting that enhanced virus replication efficiency and
viral spreading within the tumor tissue may drastically
improve therapeutical outcome. In this study, we gener-
ated a series of recombinant VACVs with different repli-
cation efficiency, which allowed us to evaluate the
correlation between virus replication efficiency and ther-
apeutical efficacy. The results described here indicated
that enhanced virus replication efficiency resulted in
enhanced tumor cell killing in cell cultures and similarly
enhanced virus replication in tumor xenografts, yielding
enhanced therapeutical efficacy. These data further
strengthen previous reports that viral oncolysis is the
most critical in tumor rejection and elimination [32].
Safety is a major concern for any cancer therapeutics.
During the past years, strategies have been developed to
enhance tumor selectivity and clinical safety of oncolytic
viruses [3]. These strategies include: 1) inactivation of viral
genes; 2) transcriptional targeting; 3) regulation of mRNA
stability; 4) mRNA translational control; and 5) transduc-
tional targeting. Inactivation of viral genes is the main
strategy currently used to enhance tumor specific replica-
tion of VACV strains [8]. However, it was reported that an
increase in attenuation resulted in a decrease in therapeu-
tic efficacy [9]. Therefore, it is important to fine balance
virulence and efficacy. GLV-1h68 was shown to be safe in
numerous tumor xenograft models. Here, we showed that
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1h68 resulted in increased virulence in mice. Although
removal of one of the three inserted foreign gene expres-
sion cassettes seemed not to significantly enhance virus
virulence, removal of two of the three foreign gene expres-
sion cassettes simultaneously resulted in consistently
increased virus virulence. Removal of all three foreign
gene expression cassettes at the same time resulted in a
virus strain with a significant increase in virus virulence.
The foreign gene expression cassettes inserted into GLV-
1h68 seems to help limit virus virulence in mice.
Conclusions
Taken together, we have shown that virus promoter dri-
ven expression of foreign genes did in fact attenuate
VACV replication. We found that virus replication effi-
ciency was inversely proportionate to the added strength
of promoters linked to foreign genes inserted into the
viral genome. Thus, we propose that VACV replication
can be fine tuned through carefully choosing the strength
of promoters added to the VACV genome for the expres-
sion of foreign genes. Furthermore, VACV replication
efficiency in cell cultures paralleled cytotoxicity in cell
cultures, and importantly, replication efficiency in tumors
as well as therapeutic efficacy in nude mice. However,
enhanced virus replication efficiency in cell cultures
resulted in increased virulence in mice.
In conclusion, GLV-1h68 seems to have well balanced
replication efficiency and minimum virulence in mice to
achieve highly efficacious tumor rejection in nude mice
with human xenografts. Virus strain attenuation by
insertion of additional viral promoters of different
strength into the VACV genome may result in rationally
designed safe attenuated therapeutic strains, presumably
due to competition for VACV RNA polymerase and cel-
lular translation machinery required to facilitate tran-
scription and translation of viral genes.
Acknowledgements
We thank Terry Trevino for excellent technical support and Boris Minev for
critical reading of the manuscript. This work was supported by grants from
Genelux Corporation (R&D facility in San Diego, CA).
Author details
1Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA.
2Department of Radiation Oncology, Rebecca and John Moores
Comprehensive Cancer Center, University of California, San Diego, CA 92093,
USA.
3Rudolph Virchow Center for Experimental Biomedicine, Department of
Biochemistry and Institute for Molecular Infection Biology, University of
Würzburg, D-97074 Würzburg, Germany.
Authors’ contributions
NGC participated in the design of study, carried out the experiments
including construction of the F14.5L, A56R shuttle vectors, generation of the
recombinant vaccinia viruses, virus replication assays, cytotoxicity assays, and
virus titrations, performed the statistical analysis and interpretation of data,
and drafted the manuscript. YAY was involved in the animal studies. QZ
constructed the J2R shuttle vector. AAS conceived of the study, participated
in its design and coordination, and prepared the final version of manuscript.
All authors read and approved the final manuscript.
Competing interests
Nanhai G. Chen, Yong A. Yu, Qian Zhang, and Aladar A. Szalay are affiliated
with Genelux Corporation.
Received: 12 September 2011 Accepted: 27 September 2011
Published: 27 September 2011
References
1. Cancer fact sheet. [http://www.who.int/mediacentre/factsheets/fs297].
2. Cancer Facts & Figures 2010. [http://www.cancer.org/acs/groups/content/
@nho/documents/document/acspc-024113.pdf].
3. Chen NG, Szalay AA: Oncolytic virotherapy of cancer. In Cancer
Managment in Man: Chemotherapy, Biological Therapy, Hyperthermia and
Supporting Measures. Volume 13. Edited by: Minev BR. New York: Springer;
2011:295-316, [Nasir A, Yeatman TJ (Series Editor) Cancer Growth and
Progression].
4. Kirn DH, Thorne SH: Targeted and armed oncolytic poxviruses: a novel
multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009,
9:64-71.
5. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID: Smallpox and its
eradication Geneva: World Health Organization; 1988.
6. Levaditi C, Nicolau S: Sur le culture du virus vaccinal dans les neoplasmes
epithelieux. CR Soc Biol 1922, 86:928.
7. Southam CM: Present status of oncolytic virus studies. Trans N Y Acad Sci
1960, 22:657-673.
8. Chen NG, Szalay AA: Oncolytic vaccinia virus: a theranostic agent for
cancer. Future Virol 2010, 5:763-784.
9. Yang S, Guo ZS, O’Malley ME, Yin X, Zeh HJ, Bartlett DL: A new
recombinant vaccinia with targeted deletion of three viral genes: its
safety and efficacy as an oncolytic virus. Gene Ther 2007, 14:638-647.
10. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM,
Szalay AA: Eradication of solid human breast tumors in nude mice with
an intravenously injected light-emitting oncolytic vaccinia virus. Cancer
Res 2007, 67:10038-10046.
11. Zhang Q, Liang C, Yu YA, Chen N, Dandekar T, Szalay AA: The highly
attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative
genomic features and the contribution of F14.5L inactivation. Mol Genet
Genomics 2009, 282:417-435.
12. Rathinavelu P, Malave A, Raney SR, Hurst J, Roberson CT, Rathinavelu A:
Expression of mdm-2 oncoprotein in the primary and metastatic sites of
mammary tumor (GI-101) implanted athymic nude mice. Cancer Biochem
Biophys 1999, 17:133-146.
13. Horton RM, Ho SN, Pullen JK, Hunt HD, Cai Z, Pease LR: Gene splicing by
overlap extension. Methods Enzymol 1993, 217:270-279.
14. Chen N, Zhang Q, Yu YA, Stritzker J, Brader P, Schirbel A, Samnick S,
Serganova I, Blasberg R, Fong Y, Szalay AA: A novel recombinant vaccinia
virus expressing the human norepinephrine transporter retains oncolytic
potential and facilitates deep-tissue imaging. Mol Med 2009, 15:144-151.
15. Chakrabarti S, Sisler JR, Moss B: Compact, synthetic, vaccinia virus early/
late promoter for protein expression. Biotechniques 1997, 23:1094-1097.
16. Lin SF, Yu Z, Riedl C, Woo Y, Zhang Q, Yu YA, Timiryasova T, Chen N,
Shah JP, Szalay AA, et al: Treatment of anaplastic thyroid carcinoma in
vitro with a mutant vaccinia virus. Surgery 2007, 142:976-983, discussion
976-983.
17. Kelly KJ, Woo Y, Brader P, Yu Z, Riedl C, Lin SF, Chen N, Yu YA, Rusch VW,
Szalay AA, Fong Y: Novel oncolytic agent GLV-1h68 is effective against
malignant pleural mesothelioma. Hum Gene Ther 2008, 19:774-782.
18. Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L, Zhang Q, Yu YA,
Chen N, Szalay AA, et al: Oncolytic vaccinia virotherapy of anaplastic
thyroid cancer in vivo. J Clin Endocrinol Metab 2008, 93:4403-4407.
19. Gentschev I, Stritzker J, Hofmann E, Weibel S, Yu YA, Chen N, Zhang Q,
Bullerdiek J, Nolte I, Szalay AA: Use of an oncolytic vaccinia virus for the
treatment of canine breast cancer in nude mice: preclinical
development of a therapeutic agent. Cancer Gene Ther 2009, 16:320-328.
20. Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y, Szalay AA: Regression
of human pancreatic tumor xenografts in mice after a single systemic
injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther 2009,
8:141-151.
Chen et al. Journal of Translational Medicine 2011, 9:164
http://www.translational-medicine.com/content/9/1/164
Page 10 of 1121. Yu Z, Li S, Brader P, Chen N, Yu YA, Zhang Q, Szalay AA, Fong Y, Wong RJ:
Oncolytic vaccinia therapy of squamous cell carcinoma. Mol Cancer 2009,
8:45.
22. Gentschev I, Donat U, Hofmann E, Weibel S, Adelfinger M, Raab V, Heisig M,
Chen N, Yu YA, Stritzker J, Szalay AA: Regression of human prostate
tumors and metastases in nude mice following treatment with the
recombinant oncolytic vaccinia virus GLV-1h68. J Biomed Biotechnol 2010,
2010:489759.
23. Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, Yu YA, Zhang Q,
Bullerdiek J, Nolte I, et al: Significant Growth Inhibition of Canine
Mammary Carcinoma Xenografts following Treatment with Oncolytic
Vaccinia Virus GLV-1h68. J Oncol 2010, 2010:736907.
24. Seubert CM, Stritzker J, Hess M, Donat U, Sturm JB, Chen N, von Hof JM,
Krewer B, Tietze LF, Gentschev I, Szalay AA: Enhanced tumor therapy using
vaccinia virus strain GLV-1h68 in combination with a beta-galactosidase-
activatable prodrug seco-analog of duocarmycin SA. Cancer Gene Ther
2011, 18:42-52.
25. Izmailyan R, Chang W: Vaccinia virus WR53.5/F14.5 protein is a new
component of intracellular mature virus and is important for calcium-
independent cell adhesion and vaccinia virus virulence in mice. J Virol
2008, 82:10079-10087.
26. Buller RM, Chakrabarti S, Cooper JA, Twardzik DR, Moss B: Deletion of the
vaccinia virus growth factor gene reduces virus virulence. J Virol 1988,
62:866-874.
27. Shida H, Hinuma Y, Hatanaka M, Morita M, Kidokoro M, Suzuki K,
Maruyama T, Takahashi-Nishimaki F, Sugimoto M, Kitamura R, et al: Effects
and virulences of recombinant vaccinia viruses derived from attenuated
strains that express the human T-cell leukemia virus type I envelope
gene. J Virol 1988, 62:4474-4480.
28. Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J, Sun YY,
Roy DG, Rintoul JL, Daneshmand M, et al: Targeting Tumor Vasculature
With an Oncolytic Virus. Mol Ther 2011, 886-94.
29. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA,
Vile RG: The case of oncolytic viruses versus the immune system: waiting
on the judgment of Solomon. Hum Gene Ther 2009, 20:1119-1132.
30. Parato KA, Lichty BD, Bell JC: Diplomatic immunity: turning a foe into an
ally. Curr Opin Mol Ther 2009, 11:13-21.
31. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH: Targeting of interferon-
beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
PLoS Med 2007, 4:e353.
32. Weibel S, Raab V, Yu YA, Worschech A, Wang E, Marincola FM, Szalay AA:
Viral-mediated oncolysis is the most critical factor in the late-phase of
the tumor regression process upon vaccinia virus infection. BMC Cancer
2011, 11:68.
33. Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J,
Galivo F, Harrington KJ, Pandha HS, et al: Immune-mediated antitumor
activity of reovirus is required for therapy and is independent of direct
viral oncolysis and replication. Clin Cancer Res 2009, 15:4374-4381.
doi:10.1186/1479-5876-9-164
Cite this article as: Chen et al.: Replication efficiency of oncolytic
vaccinia virus in cell cultures prognosticates the virulence and
antitumor efficacy in mice. Journal of Translational Medicine 2011 9:164.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Chen et al. Journal of Translational Medicine 2011, 9:164
http://www.translational-medicine.com/content/9/1/164
Page 11 of 11